Trials / Completed
CompletedNCT00615940
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Heidelberg Pharma AG · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, double-blind, placebo controlled phase II trial is studying how well capecitabine works when given in combination with WX-671 or when given alone in treating patients receiving first-line therapy for her2negative metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WX-671 | capsules taken per os once daily until progression or toxicity |
| DRUG | placebo | capsule taken per os once daily until progression or toxicity |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-12-01
- Completion
- 2012-04-01
- First posted
- 2008-02-14
- Last updated
- 2014-02-28
Locations
20 sites across 5 countries: United States, Belgium, Brazil, Germany, Israel
Source: ClinicalTrials.gov record NCT00615940. Inclusion in this directory is not an endorsement.